TricDB

cabozantinib

Drug Code : 2202132113
Drug Brand : Cabometyx
Company : Exelixis Inc
Approved by : FDA, NCCN
Approval Time : Nov. 29, 2012
Direct Target : FLT1,KDR,FLT4,KIT,FLT3,RET,MET,NTRK2,AXL,ROS1,TYRO3,MERTK,TEK
Drug Type : Multi-target inhibitor
Gene : RET
Alteration : Positive Expression
Indications : Cabozantinib was approved to be used for the treatment of patients with progressive metastatic medullary thyroid cancer.
Mechanism Of Action :
In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.
Clinical Trial : NCT00704730
Dosage : The recommended dose of cabozantinib is 140 mg once daily. Patients should not eat for least 2 hours before and 1 hour after taking the medication. There are no specific contraindications to cabozantinib use.
Reference Source :
Structure :
 Related Targets and Diseases
Drug Name Gene Disease Negative Genotypes Drug Brand Drug Type
Reference List :


Approval Notifications
Hot words
Terms of Use
Privacy Policy
biomeddb.org © 2025 Hubei University
Email: argyjbao@hotmail.com & skysky@hubu.edu.cn